Lanqing Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lanqing Yang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Bing Wu
Department of Radiology, West China Hospital, Sichuan University, Chengdu, China
3 shared publications - Dan Liu
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China
2 shared publications - Xin Fang
Department of Radiology
2 shared publications - Bin Song
Department of Radiology, West China Hospital, Sichuan University, Chengdu, China
1 shared publication Chunchao Xia
Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China
1 shared publication- Chunchao Xia
Department of Radiology, West China Hospital of Sichuan University, Chengdu, China
1 shared publication
Latest Publications
- 20 August 2025
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 62 (6) , 1742-1751
Assessing the Diagnostic Value of MRI T1rho Mapping in Predicting Molecular Prognostic Biomarkers and Subtypes of Breast Cancer
Background: Prognostic factors and molecular subtypes are important in treatment planning and predicting response to therapy in breast cancer, and the exploration of noninvasive imaging methods to characterize breast cancer has been ongoing. Purpose: To evaluate the use of T1rho mapping in predicting the status of prognostic biomarkers and molecular subtypes of breast cancer. Study Type: Prospective. Subjects: Ninety One women with breast tumors. Field Strength/Sequence: 3T, T1 rho prepared balanced turbo field echo sequence. Assessment: Mean T1rho values were compared between positive and negative status of prognostic biomarkers [estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and proliferation index (Ki‐67)] and molecular subtypes. Statistical Tests: Independent t test, one‐way analysis of variance, Kruskal–Wallis test, chi‐square test, Fisher exact test, and receiver operating characteristic (ROC) analysis. Results: Mean T1rho values were significantly higher in ER‐negative compared to ER‐positive tumors (70 ± 6.769 vs. 55 ± 10.791 ms), in PR‐negative compared to PR‐positive tumors (68.48 ± 9.563 vs. 60.46 ± 10.099 ms), and in high Ki‐67 proliferation compared to low Ki‐67 proliferation tumors (66.59 ± 8.994 vs. 57.77 ± 11.501 ms). Significant negative correlations were observed between ER and PR statuses and T1rho values ( r s = 0.416 and 0.392, respectively). The Ki‐67 status was significantly positively correlated with T1rho values ( r s = 0.369). The Luminal A subtype had a significantly lower T1rho value than other subtypes (56.46 ± 10.553 vs. 66.58 ± 9.204 ms). The Luminal B subtype had significantly lower T1rho values than the triple‐negative (TN) subtype (63.957 ± 9.794 vs. 72.237 ± 8.229 ms). The TN subtype had a significantly higher T1rho value than luminal subtypes (72.237 ± 8.229 vs. 62.903 ± 10.289 ms). The T1rho values had good diagnostic performance in identifying Luminal A and TN breast cancers with areas under the ROC curve of 0.767 and 0.776. Data Conclusion: T1rho mapping has the potential to be a non‐invasive imaging biomarker for evaluating the prognostic biomarkers and molecular subtypes of breast cancer.
- 20 August 2025
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 62 (6) , 1742-1751
Assessing the Diagnostic Value of MRI T1rho Mapping in Predicting Molecular Prognostic Biomarkers and Subtypes of Breast Cancer
Background: Prognostic factors and molecular subtypes are important in treatment planning and predicting response to therapy in breast cancer, and the exploration of noninvasive imaging methods to characterize breast cancer has been ongoing. Purpose: To evaluate the use of T1rho mapping in predicting the status of prognostic biomarkers and molecular subtypes of breast cancer. Study Type: Prospective. Subjects: Ninety One women with breast tumors. Field Strength/Sequence: 3T, T1 rho prepared balanced turbo field echo sequence. Assessment: Mean T1rho values were compared between positive and negative status of prognostic biomarkers [estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and proliferation index (Ki‐67)] and molecular subtypes. Statistical Tests: Independent t test, one‐way analysis of variance, Kruskal–Wallis test, chi‐square test, Fisher exact test, and receiver operating characteristic (ROC) analysis. Results: Mean T1rho values were significantly higher in ER‐negative compared to ER‐positive tumors (70 ± 6.769 vs. 55 ± 10.791 ms), in PR‐negative compared to PR‐positive tumors (68.48 ± 9.563 vs. 60.46 ± 10.099 ms), and in high Ki‐67 proliferation compared to low Ki‐67 proliferation tumors (66.59 ± 8.994 vs. 57.77 ± 11.501 ms). Significant negative correlations were observed between ER and PR statuses and T1rho values ( r s = 0.416 and 0.392, respectively). The Ki‐67 status was significantly positively correlated with T1rho values ( r s = 0.369). The Luminal A subtype had a significantly lower T1rho value than other subtypes (56.46 ± 10.553 vs. 66.58 ± 9.204 ms). The Luminal B subtype had significantly lower T1rho values than the triple‐negative (TN) subtype (63.957 ± 9.794 vs. 72.237 ± 8.229 ms). The TN subtype had a significantly higher T1rho value than luminal subtypes (72.237 ± 8.229 vs. 62.903 ± 10.289 ms). The T1rho values had good diagnostic performance in identifying Luminal A and TN breast cancers with areas under the ROC curve of 0.767 and 0.776. Data Conclusion: T1rho mapping has the potential to be a non‐invasive imaging biomarker for evaluating the prognostic biomarkers and molecular subtypes of breast cancer.
- Open Access
- 3 December 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
A Bounding Box-Based Radiomics Model for Detecting Occult Peritoneal Metastasis in Advanced Gastric Cancer: A Multicenter Study
Purpose: To develop a bounding box (BBOX)-based radiomics model for the preoperative diagnosis of occult peritoneal metastasis (OPM) in advanced gastric cancer (AGC) patients.Materials and Methods: 599 AGC patients from 3 centers were retrospectively enrolled and were divided into training, validation, and testing cohorts. The minimum circumscribed rectangle of the ROIs for the largest tumor area (R_BBOX), the nonoverlapping area between the tumor and R_BBOX (peritumoral area; PERI) and the smallest rectangle that could completely contain the tumor determined by a radiologist (M_BBOX) were used as inputs to extract radiomic features. Multivariate logistic regression was used to construct a radiomics model to estimate the preoperative probability of OPM in AGC patients.Results: The M_BBOX model was not significantly different from R_BBOX in the validation cohort [AUC: M_BBOX model 0.871 (95% CI, 0.814–0.940) vs. R_BBOX model 0.873 (95% CI, 0.820–0.940); p = 0.937]. M_BBOX was selected as the final radiomics model because of its extremely low annotation cost and superior OPM discrimination performance (sensitivity of 85.7% and specificity of 82.8%) over the clinical model, and this radiomics model showed comparable diagnostic efficacy in the testing cohort.Conclusions: The BBOX-based radiomics could serve as a simpler reliable and powerful tool for the preoperative diagnosis of OPM in AGC patients. And M_BBOX-based radiomics is simpler and less time consuming.
- 3 December 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessA Bounding Box-Based Radiomics Model for Detecting Occult Peritoneal Metastasis in Advanced Gastric Cancer: A Multicenter Study
Purpose: To develop a bounding box (BBOX)-based radiomics model for the preoperative diagnosis of occult peritoneal metastasis (OPM) in advanced gastric cancer (AGC) patients.Materials and Methods: 599 AGC patients from 3 centers were retrospectively enrolled and were divided into training, validation, and testing cohorts. The minimum circumscribed rectangle of the ROIs for the largest tumor area (R_BBOX), the nonoverlapping area between the tumor and R_BBOX (peritumoral area; PERI) and the smallest rectangle that could completely contain the tumor determined by a radiologist (M_BBOX) were used as inputs to extract radiomic features. Multivariate logistic regression was used to construct a radiomics model to estimate the preoperative probability of OPM in AGC patients.Results: The M_BBOX model was not significantly different from R_BBOX in the validation cohort [AUC: M_BBOX model 0.871 (95% CI, 0.814–0.940) vs. R_BBOX model 0.873 (95% CI, 0.820–0.940); p = 0.937]. M_BBOX was selected as the final radiomics model because of its extremely low annotation cost and superior OPM discrimination performance (sensitivity of 85.7% and specificity of 82.8%) over the clinical model, and this radiomics model showed comparable diagnostic efficacy in the testing cohort.Conclusions: The BBOX-based radiomics could serve as a simpler reliable and powerful tool for the preoperative diagnosis of OPM in AGC patients. And M_BBOX-based radiomics is simpler and less time consuming.
- 10 January 2020
- Published by SAGE Publications in Acta Radiologica
- Vol. 61 (9) , 1155-1164
The role of readout-segmented echo-planar imaging-based diffusion-weighted imaging in evaluating tumor response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy
Background: Accurate assessment of tumor response in rectal cancer could help individualize treatment. Purpose: To evaluate the role of diffusion-weighted imaging (DWI) based on readout-segmented echo-planar imaging (rs-EPI) in assessing tumor response after neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC). Material and Methods: Sixty-three patients with LARC who received neoadjuvant CRT and surgery were enrolled retrospectively. They all underwent pre- and post-CRT magnetic resonance examinations, including DWI using rs-EPI. According to pathological results, patients were grouped as pathological complete responder (pCR, n = 16) and non-pCR (n = 47). Visual assessment of residual tumor and whole-tumor histogram analysis of pre- and post-CRT apparent diffusion coefficient (ADC) map was performed by two radiologists; tumor volume on ADC map was also recorded. Results: Overall inter-observer agreement was good for histogram analysis (ICC = 0.543–0.999). Tumor volume reduction rate on ADC map showed no significant difference between the two groups ( P = 0.468). Post-CRT mean, quantile values, and their percentage changes were higher in the pCR group (all P < 0.001). Post-CRT mean value had a good diagnostic power in selecting pCR (AUC = 0.855), with a cut-off value of 1.345 × 10−3 mm2/s, yielding a sensitivity of 83%, specificity of 81.3%. Post-CRT 95% quantile value had the highest AUC (AUC = 0.868) among quantile values, and a higher specificity (87.5% vs. 81.3%) than mean value with comparable overall diagnostic performance ( P = 0.563). Visual assessment showed a sensitivity of 85.1%, specificity of 68.8% in selecting pCR. Conclusion: Quantitative ADC value of rs-EPI DWI could reliably evaluate tumor response in patients with LARC. Post-CRT 95% quantile ADC value could help mean value to more accurately identify pCR.
- 10 January 2020
- Published by SAGE Publications in Acta Radiologica
- Vol. 61 (9) , 1155-1164
The role of readout-segmented echo-planar imaging-based diffusion-weighted imaging in evaluating tumor response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy
Background: Accurate assessment of tumor response in rectal cancer could help individualize treatment. Purpose: To evaluate the role of diffusion-weighted imaging (DWI) based on readout-segmented echo-planar imaging (rs-EPI) in assessing tumor response after neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC). Material and Methods: Sixty-three patients with LARC who received neoadjuvant CRT and surgery were enrolled retrospectively. They all underwent pre- and post-CRT magnetic resonance examinations, including DWI using rs-EPI. According to pathological results, patients were grouped as pathological complete responder (pCR, n = 16) and non-pCR (n = 47). Visual assessment of residual tumor and whole-tumor histogram analysis of pre- and post-CRT apparent diffusion coefficient (ADC) map was performed by two radiologists; tumor volume on ADC map was also recorded. Results: Overall inter-observer agreement was good for histogram analysis (ICC = 0.543–0.999). Tumor volume reduction rate on ADC map showed no significant difference between the two groups ( P = 0.468). Post-CRT mean, quantile values, and their percentage changes were higher in the pCR group (all P < 0.001). Post-CRT mean value had a good diagnostic power in selecting pCR (AUC = 0.855), with a cut-off value of 1.345 × 10−3 mm2/s, yielding a sensitivity of 83%, specificity of 81.3%. Post-CRT 95% quantile value had the highest AUC (AUC = 0.868) among quantile values, and a higher specificity (87.5% vs. 81.3%) than mean value with comparable overall diagnostic performance ( P = 0.563). Visual assessment showed a sensitivity of 85.1%, specificity of 68.8% in selecting pCR. Conclusion: Quantitative ADC value of rs-EPI DWI could reliably evaluate tumor response in patients with LARC. Post-CRT 95% quantile ADC value could help mean value to more accurately identify pCR.
- 5 July 2019
- Published by Springer Nature in European Radiology
- Vol. 29 (12) , 6469-6476
Rectal cancer: can T2WI histogram of the primary tumor help predict the existence of lymph node metastasis?
To explore if there is a correlation between T2WI histogram features of the primary tumor and the existence of regional lymph node (LN) metastasis in rectal cancer.
- 5 July 2019
- Published by Springer Nature in European Radiology
- Vol. 29 (12) , 6469-6476
Rectal cancer: can T2WI histogram of the primary tumor help predict the existence of lymph node metastasis?
To explore if there is a correlation between T2WI histogram features of the primary tumor and the existence of regional lymph node (LN) metastasis in rectal cancer.